Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.43 |
| ▸ | PI4KA | P42356 | 3/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.34 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL5542708 | 0.84 | PI4KA (0.40) | PI4KBPI4KAPI4K2BPI4K2AMAP4K4 | |
| Adenine SCHEMBL9540431 | 0.82 | PI4KA (0.39) | PI4KBPI4KAPI4K2BPI4K2AMAP4K4 | |
| Adenine SCHEMBL6294180 | 0.82 | PI4KA (0.39) | PI4KBPI4KAPI4K2BPI4K2AMAP4K4 | |
| Adenine SCHEMBL11022893 | 0.82 | EGFR (0.43) | PI4KBPI4KAPI4K2BPI4K2AMAP4K4 | |
| Adenine SCHEMBL135916 | 0.81 | ALDH1A1 (0.54) | PI4KBPI4KAPI4K2BPI4K2AMAP4K4 | |
| Adenine SCHEMBL22748483 | 0.81 | F7 (0.56) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| Adenine SCHEMBL15699 | 0.81 | F7 (0.56) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| Adenine SCHEMBL622425 | 0.81 | EGFR (0.42) | PI4KBPI4KAPI4K2BPI4K2AMAP4K4 | |
| Adenine SCHEMBL2564207 | 0.81 | F7 (0.56) | PI4KBPI4KAPI4K2BPI4K2AEGFR | |
| Adenine SCHEMBL11342620 | 0.80 | PI4KA (0.45) | PI4KBPI4KAPI4K2BPI4K2AMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288052-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2011-11-24 | — | — | US | disclosed |
| EP-2386551-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | Fasgen Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386550-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | Fasgen Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-8038089-B2 | Leader member in recording tape cartridge, manufacturing method thereof, and recording tape cartridge | FUJIFILM CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-D647106-S1 | Display module for an electronic device | APPLE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1017835-B1 | CYTOCHROME P450 REDUCTASE FOR THE ENHANCEMENT OF P450-BASED ANTI-CANCER GENE THERAPY | UNIV BOSTON (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2285215-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | Fasgen, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100168176-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FASGEN LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100120901-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FASGEN,INC (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| US-5614551-A | Inhibitors of fatty acid synthesis as antimicrobial agents | THE JOHNS HOPKINS UNIVERSITY (US) | 1997-03-25 | — | — | US | disclosed |
| EP-0738107-A1 | INHIBITORS OF FATTY ACID SYNTHESIS AS ANTIMICROBIAL AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5547835-A | USING THE SANGER SEQUENCING STRATEGY AND ASSEMBLING THE SEQUENCE INFORMATION BY ANALYSIS OF THE NESTED FRAGMENTS OBTAINED BY BASE-SPECIFIC CHAIN TERMINATION VIA THEIR DIFFERENT MOLECULAR MASSES | SEQUENOM, INC. (US) | 1996-08-20 | — | — | US | disclosed |
| EP-0689610-A1 | DNA SEQUENCING BY MASS SPECTROMETRY VIA EXONUCLEASE DEGRADATION | SEQUENOM, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0679196-A1 | DNA SEQUENCING BY MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1995019706-A1 | INHIBITORS OF FATTY ACID SYNTHESIS AS ANTIMICROBIAL AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0651636-A1 | CHEMOTHERAPY FOR CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994021822-A1 | DNA SEQUENCING BY MASS SPECTROMETRY VIA EXONUCLEASE DEGRADATION | SEQUENOM, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994016101-A2 | DNA SEQUENCING BY MASS SPECTROMETRY | KOESTER HUBERT (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994002108-A1 | CHEMOTHERAPY FOR CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288052-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | C1S, C1R, MC2R | PI4KB 4682/4885PI4KA 4710/4885PI4K2B 4630/4885 |
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | CYP3A7, DHCR7, CYP2A7 | PI4KB 4702/4885PI4KA 4623/4885PI4K2B 4088/4885 |
| US-20100120901-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | CPT1A, CPT1B, CPT2 | PI4KB 4528/4885PI4KA 4697/4885PI4K2B 4144/4885 |
| US-20100168176-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | AOC3, CYP2B6, CBR3 | PI4KB 3714/4885PI4KA 3540/4885PI4K2B 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.